Silent Epidemic: Cannabis Compounds to the Rescue?

Two non-intoxicating compounds found in cannabis plants could become the first approved medication for a silent liver epidemic affecting roughly one in three American adults.

Story Snapshot

Cannabidiol (CBD) and cannabigerol (CBG) reduced liver fat and improved metabolic health in preclinical research at Hebrew University of Jerusalem
The study targets metabolic dysfunction-associated steatotic liver disease (MASLD), a condition plaguing 30-33% of adults worldwide with zero FDA-approved drugs
CBG outperformed CBD in reducing body fat, improving insulin sensitivity, and lowering cholesterol and LDL levels
Researchers identified dual mechanisms: recharging liver energy reserves and clearing harmful lipid buildup through cellular cleanup processes
Human clinical trials remain necessary before these plant-based compounds can reach pharmacy shelves

The Liver Crisis Hiding in Plain Sight

MASLD quietly ravages livers across America and beyond, yet most victims remain blissfully unaware until serious damage occurs. This condition, previously known as non-alcoholic fatty liver disease, stems from obesity, insulin resistance, and metabolic syndrome rather than alcohol abuse. The disease progresses from simple fat accumulation to inflammation, fibrosis, and potentially cirrhosis. Despite affecting approximately one-third of the adult population globally, the medical community offers patients only lifestyle modification advice. No pharmaceutical company has successfully brought an approved MASLD drug to market, leaving a treatment void that researchers at Hebrew University sought to fill.

Cannabis Science Beyond the High

The research team led by Professor Joseph Tam at Hebrew University’s Multidisciplinary Center for Cannabinoid Research focused on CBD and CBG precisely because these cannabinoids produce zero psychoactive effects. Unlike THC, which dominates cannabis headlines and legalization debates, CBD and CBG work quietly within the body’s metabolic machinery. The March 2026 study published in the British Journal of Pharmacology tested these compounds on mice fed high-fat diets designed to mimic human MASLD conditions. The results revealed something previous cannabinoid research had missed entirely: a specific dual-action mechanism targeting both energy metabolism and cellular waste removal in diseased livers.

Recharging the Liver’s Backup Battery

Professor Tam’s team discovered that CBD and CBG enhance hepatic energy reserves through phosphocreatine buffering, essentially recharging the liver’s backup power supply. Simultaneously, these compounds restore lysosomal cathepsin activity, which functions as the cell’s waste disposal system. This cleanup process clears harmful lipids including triglycerides and ceramides that accumulate in fatty liver disease. The researchers documented measurable reductions in liver fat alongside improvements in glucose metabolism and insulin function. CBG demonstrated superior performance across multiple metrics, particularly in reducing overall body fat mass and improving cholesterol profiles compared to CBD alone.

The Path From Laboratory Mice to Human Medicine

The preclinical nature of this research demands cautious interpretation. Mouse models reliably predict human responses in many disease contexts, but translation failures plague pharmaceutical development. Professor Tam emphasized the team’s goal to advance these findings into clinical trials that would test CBD and CBG safety and efficacy in actual MASLD patients. No dosing protocols exist for human use, no long-term safety data has been collected, and potential drug interactions remain unexplored. Patients currently self-medicating with cannabis products face unknown risks without clinical guidance. The research team stressed that human translation studies represent the critical next step before any therapeutic recommendations can responsibly emerge.

Cannabis compounds could reverse disease affecting one-third of adults https://t.co/HGDrGVBVfy #FoxNews

— Rob Klippel (@rjklip) March 10, 2026

The economic stakes surrounding MASLD treatment dwarf most pharmaceutical markets. With roughly one-third of adults affected globally and zero approved medications available, the first successful drug could generate billions in revenue while addressing genuine medical need. Israel’s leadership in cannabinoid research, exemplified by Hebrew University’s specialized center, positions the nation to influence international drug approval processes and cannabis regulation. The shift from lifestyle intervention as the sole treatment option to potential pharmacotherapy represents a fundamental change in how medicine approaches this metabolic disorder. Whether CBD and CBG fulfill their preclinical promise remains uncertain, but the research opens doors for plant-based metabolic therapies that extend far beyond traditional cannabis applications.